Drug intelligence / Profile preview

PMS-004

Development stage: Preclinical
Lead developer: Primary Peptides
Modality: Peptides

Overview

PMS-004 is an innovative peptide therapeutic developed by Primary Peptides Inc. and licensed to Qingdao Primedicine Pharmaceutical Co. Ltd. It acts as a JNK kinase inhibitor and is being developed for the treatment of myocardial infarction. Qingdao Primedicine Pharmaceutical holds exclusive rights for development and commercialization in Greater China (mainland, Hong Kong, Macau, and Taiwan), while Primary Peptides retains rights in all other markets. Preclinical pharmacodynamic evaluations in animal models have shown protective effects on myocardial cells, and preclinical research was slated to officially launch in the second half of 2020.

Targets

JNK (Mitogen-activated protein kinase kinase kinase family)

Beyond the preview

Go deeper on PMS-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PMS-004.

Explore the full profile